Articles from Kura Oncology, Inc.

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML –
By Kura Oncology, Inc. · Via GlobeNewswire · January 11, 2026
Articles from Kura Oncology, Inc. | The Union Democrat